Articles Tagged With:
-
HHS: Efforts to Make Healthcare Safer Saves Lives
Report highlights 21% decline in hospital-acquired conditions over five-year period.
-
Male Hypogonadism
Testosterone replacement therapy is a growing industry that deserves discussion between patients and their healthcare providers. Recently, many insights into new formulations, advertising, and potential risks have heightened the controversy surrounding low testosterone syndrome, appropriate diagnosis, and risks and benefits of testosterone supplementation. A plethora of non-regulated supplements termed “testosterone boosters” are being marketed directly to the public without adequate assessment. Therefore, it is important for healthcare providers to be familiar with how to conduct and interpret diagnostic tests as well as with appropriate use of TRT as established by various medical organizations, including the Endocrine Society. This review will discuss the definitions, pathophysiology, causes, clinical manifestations, appropriate diagnostic testing procedures, and the role of testosterone supplementation with currently available formulations, with special attention to efficacy and adverse effects in hypogonadism in men.
-
People with Mental Illness Often Excluded from Clinical Trials
If a medication for major depression has a dangerous adverse interaction with a different medication that’s being studied in a clinical trial, will it be discovered by researchers and reported in the literature? Not likely, if no one enrolled in the study has major depression.
-
IRB Designs Process to Separate QI from HSR
The most commonly asked question of the Intermountain Healthcare IRB in Salt Lake City has been: “Is this quality improvement or is it research?”
-
When it was Time to Standardize, IRB Went With a P&G Committee
Collaboration and consolidation of IRBs likely will be an ongoing trend that necessitates action to reduce problems and improve streamlining — in other words, best practices.
-
Meeting Management ABCs From an Expert IRB Chair
After 32 years as an IRB member and 20 years as chair, one IRB expert says the key to IRB meeting success could be boiled down to one word: Respect.
-
Research on Brain Scan Risk of Alzheimer’s an Ethical Challenge
While different than genetic signs for dementia, biomarker information found in research brain scans also can suggest heightened risk for developing Alzheimer’s disease, and thus the disclosure or withholding of results raises ethical questions for IRBs and investigators.
-
Clinical Trial Addresses the Tricky Process of Revealing Genetic Risk Factors for Alzheimer’s
Genetic research that could prevent or treat Alzheimer’s are under study. The caveat is that the human subjects recruited into trials must be willing to know if they carry the DNA markers that may predispose them to subsequent dementia.
-
Culture Most Important in Preventing Falls with Elderly
The organization’s culture is the factor most determining the liability risk of a facility or community serving the elderly, according to a recent report from CNA Financial Corporation in Chicago.
-
Tell Staff How Safety Reports Make a Difference
Hospital staff will report safety concerns more when they are informed of how their previous reports helped improve patient safety, according to a recent report from St. Jude Children’s Research Hospital in Memphis.